Related Experiment Video

Updated: Jun 12, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

9.9K

177Lu-PSMA-617 for metastatic prostate cancer: aiming for the right spot

Joaquin Mateo1, Amado J Zurita2

  • 1Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital Campus, Barcelona 08035, Spain.

Lancet (London, England)
|September 18, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K

Related Experiment Videos

Last Updated: Jun 12, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

9.9K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K

Articles linked to this work by shared authors, journal, and citation graph.

Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program.

NPJ precision oncology·2026

Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers.

iScience·2026

PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer.

The New England journal of medicine·2026

Expert practical recommendations for optimising tumour and germline testing of homologous recombination repair gene mutations in metastatic prostate cancer.

Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia·2026

Role of the cross-regulation between Wnt pathway activation and androgen receptor signaling in prostate cancer treatment resistance.

Cell death and differentiation·2026

A Phase 2, Randomized, Controlled Trial of Best Systemic Therapy Versus Best Systemic Therapy with Definitive Treatment of the Primary Tumor in Metastatic Prostate Cancer.

European urology·2026

Precision prevention and early detection: framework for a new clinical cancer control pathway.

Lancet (London, England)·2026

Switch to injectable cabotegravir-rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial.

Lancet (London, England)·2026

Pharmaceutical-industry R&D and hospital financial performance in Japan: a fixed-effects analysis.

Health policy OPEN·2026

[THE PHARMACEUTICAL HUMANITIES IN RUSSIA AND FOR RUSSIA].

Problemy sotsial'noi gigieny, zdravookhraneniia i istorii meditsiny·2026

Research Needs in Philippine Pharmaceutical Sciences: A Qualitative Perspective from Regulatory and Clinical Research Sectors of the Pharmaceutical Industry.

Acta medica Philippina·2026

[The Role of Pharmaceutical Universities in Strengthening Japan's Drug Discovery Capabilities: A Pharmaceutical Industry Perspective].

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·2026

A randomized, open-label, three-period, cross-over, single intravenous or intramuscular dose, pharmacokinetics and bioequivalence study of vitamin K1 in healthy adults.

Naunyn-Schmiedeberg's archives of pharmacology·2026

Academic Influence and Industry Funding in Platelet-Rich Plasma Injections: Coauthorship Network Analysis.

Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us